Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Tomaralimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Tomaralimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Tomaralimab. |
| Estrone | Estrone may increase the thrombogenic activities of Tomaralimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Tomaralimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Tomaralimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Tomaralimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Tomaralimab. |
| Estriol | Estriol may increase the thrombogenic activities of Tomaralimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Tomaralimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Tomaralimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Tomaralimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Tomaralimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tomaralimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tomaralimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Tomaralimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Tomaralimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Tomaralimab. |
| Equol | Equol may increase the thrombogenic activities of Tomaralimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Tomaralimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Tomaralimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Tomaralimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Tomaralimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Tomaralimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Tomaralimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Tomaralimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Tomaralimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Tomaralimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Tomaralimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Tomaralimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Tomaralimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tomaralimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Tomaralimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Tomaralimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Tomaralimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tomaralimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tomaralimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Tomaralimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tomaralimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Tomaralimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Tomaralimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Tomaralimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tomaralimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tomaralimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Tomaralimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tomaralimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tomaralimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Tomaralimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tomaralimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Tomaralimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Tomaralimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Tomaralimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tomaralimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tomaralimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Tomaralimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Tomaralimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tomaralimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Tomaralimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tomaralimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Tomaralimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tomaralimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Tomaralimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Tomaralimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Tomaralimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tomaralimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tomaralimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Tomaralimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tomaralimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Tomaralimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Tomaralimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tomaralimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Tomaralimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tomaralimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Tomaralimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tomaralimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Tomaralimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tomaralimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Tomaralimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Tomaralimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Tomaralimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tomaralimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tomaralimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tomaralimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tomaralimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tomaralimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Tomaralimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Tomaralimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tomaralimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Tomaralimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Tomaralimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Tomaralimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Tomaralimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tomaralimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Tomaralimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tomaralimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Tomaralimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tomaralimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tomaralimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Tomaralimab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tomaralimab. |